Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 4NCT06501443LATAM LOWERS LDL-CNovartis Pharmaceuticals · HypercholesterolaemiaRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Nov 27, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06923891An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia PatientsVanguard Research Group · SchizophreniaNot yet recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Oct 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07681076Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersKaruna Therapeutics, Inc., a Bristol Myers Squibb company · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT00512122Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill PatientsKU Leuven · Critical IllnessActive, not recruitingBAXCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 2011Actual
- Interventions
- Locked
- Completion LockedPhase 4NCT04206813An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination RegimenBoston Medical Center · HPV InfectionActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT05195944Semaglutide vs SitagliptinUniversity Health Network, Toronto · Liver Transplant; ComplicationsActive, not recruitingNVOCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06119061Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular DrainageAaron Cook · Subarachnoid Hemorrhage, AneurysmalRecruitingCPIXCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06352073Dupilumab for Eosinophilic Esophagitis With Severe StricturesUniversity of North Carolina, Chapel Hill · Eosinophilic EsophagitisActive, not recruitingREGNCollaboratorSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Apr 16, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 4NCT07197762MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young AdultsEmory University · Neisseria MeningitidisRecruitingPFECollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07133880Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting BronchodilatorsUniversity of Tennessee Graduate School of Medicine · COPD (Chronic Obstructive Pulmonary Disease)RecruitingTBPHCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07884175A Study of Updated mRNA Seasonal Influenza VaccinesModernaTX, Inc. · Seasonal InfluenzaRecruitingMRNALead
- Enrollment
- Locked
- Primary completion
- Dec 7, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07863635A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsModernaTX, Inc. · SARS-CoV-2RecruitingMRNALead
- Enrollment
- Locked
- Primary completion
- Dec 11, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT05060991Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant RecipientsUniversity of California, Davis · COVID-19Active, not recruitingCDNACollaborator
- Enrollment
- Locked
- Primary completion
- Dec 24, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT04380038Viral Infection in Asthma (VIA) StudyUniversity of Virginia · AsthmaRecruitingREGNCollaborator
- Enrollment
- Locked
- Primary completion
- Jun 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT05094570Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNPUniversity of Virginia · Nasal PolypsRecruitingREGNCollaborator
- Enrollment
- Locked
- Primary completion
- Jun 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT05457257Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer...AstraZeneca · Metastatic Castration-resistant Prostate CancerActive, not recruitingAZNLeadMYGNCollaboratorMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Oct 22, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 4NCT05780905Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 DiabetesUniversity of Washington · Diabetes Mellitus, Type 2RecruitingNVOCollaborator
- Enrollment
- Locked
- Primary completion
- Mar 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06218199Diuretics vs. Afterload Reduction for Treatment of HeartLogic AlertsHeart Center Research, LLC · Heart Failure, CongestiveRecruitingBSXCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06585241A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsModernaTX, Inc. · SARS-CoV-2RecruitingMRNALead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06830668Same-Day Restart of B/F/TAF in HIV Patients After NNRTI DiscontinuationNational Center for AIDS/STD Control and Prevention, China CDC · HIV InfectionNot yet recruitingGILDCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06860633Treatment of Myasthenia Gravis Exacerbation or Crisis With EfgartigimodUniversity of Colorado, Denver · Myasthenia Gravis CrisisRecruitingARGXCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07225101Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine ProceduresUniversity of Michigan · Wound ClosureRecruitingJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Jun 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07603284Continuous Glucose Monitoring By DExcom iN PEople Followed for Type 2 DIabeTes on Insulin Therapy in the Kingdom of Saudi ArabiaDexCom, Inc. · Type 2 Diabetes on InsulinActive, not recruitingDXCMLead
- Enrollment
- Locked
- Primary completion
- Nov 2, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07606625Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye TreatmentUniversity of California, Berkeley · Dry EyeRecruitingVTRSCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07301008Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the USMedstar Health Research Institute · MigraineRecruitingPFECollaborator
- Enrollment
- Locked
- Primary completion
- Sep 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 11 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.